"Neuropsychiatric Disease and Treatment is unique among Open Access journals in accepting manuscripts on both psychiatry and neurology by spanning the diminishing gap between the two specialties."
Auckland, New Zealand (PRWEB) August 08, 2012
Thomson Reuters has recently released the 2011 Journal Citation Reports® (JCR), showing new impact factors for several of Dove Medical Press journals, including Neuropsychiatric Disease and Treatment. The JCR provides information about highly-cited, peer reviewed publications and is the source of the new Journal Impact Factors.
The 2011 impact factor for Neuropsychiatric Disease and Treatment (NDT) has been added at 1.809.
Edited by Dr. Roger M Pinder, NDT is an international, peer-reviewed journal of clinical therapeutics and pharmacology focusing on concise rapid reporting of clinical or pre-clinical studies on a range of neuropsychiatric and neurological disorders.
According to Dr. Pinder, "Neuropsychiatric Disease and Treatment is unique among Open Access journals in accepting manuscripts on both psychiatry and neurology by spanning the diminishing gap between the two specialties. Focusing on clinical research but also willing to accommodate experimental research studies which support clinical concepts, the journal publishes high quality and fully peer-reviewed original research papers as well as reviews, expert opinion, commentaries and case reports.
As Thomson Reuters quotes, "Journal Selection takes place throughout the course of a year and its goal is to identify, evaluate and select the most important and influential International and Regional journals for coverage in Thomson Reuters Web of Knowledge platform. The following year, these data are then analyzed and published in the JCR release, providing a view of how these journals are integrated, through citation, with the scholarly, multidisciplinary literature."
Dove Medical Press is a privately held publisher of 100+ open access peer-reviewed journals across the broad spectrum of science, technology and especially medicine. Dove was founded in 2003 and has offices in the United Kingdom and New Zealand, with an active presence in the USA and a network of agents in Europe, the Americas, and Southeast Asia.